Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Foghorn Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Foghorn Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 0.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Foghorn Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-3.42.
Foghorn Therapeutics Accounts Receivable Historical Data
The historical data trend for Foghorn Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Foghorn Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Foghorn Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Foghorn Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Foghorn Therapeutics Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics (Foghorn Therapeutics) Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your 